BeOne Medicines annual net profit margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Net Profit Margin Growth & History (ONC)
BeOne Medicines's net profit margin was 5.37% for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 5.37% | +22.29 pp |
| 2024 | 2024-12-31 | −16.92% | +18.94 pp |
| 2023 | 2023-12-31 | −35.86% | +105.66 pp |
| 2022 | 2022-12-31 | −141.52% | −17.59 pp |
| 2021 | 2021-12-31 | −123.93% | +402.16 pp |
| 2020 | 2020-12-31 | −526.10% | −304.56 pp |
| 2019 | 2019-12-31 | −221.53% | +118.38 pp |
| 2018 | 2018-12-31 | −339.91% | −300.85 pp |
| 2017 | 2017-12-31 | −39.06% | +11102.72 pp |
| 2016 | 2016-12-31 | −11,141.78% | −10494.07 pp |
| 2015 | 2015-12-31 | −647.71% | −507.49 pp |
| 2014 | 2014-12-31 | −140.22% | — |
BeOne Medicines quarterly net profit margin
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 13.90% | +6.73 pp |
| Q1 2026 | 2026-03-31 | 15.02% | +14.91 pp |
| Q4 2025 | 2025-12-31 | 4.44% | +17.91 pp |
| Q3 2025 | 2025-09-30 | 8.84% | +20.96 pp |
| Q2 2025 | 2025-06-30 | 7.17% | +20.13 pp |
| Q1 2025 | 2025-03-31 | 0.11% | +33.53 pp |
| Q4 2024 | 2024-12-31 | −13.47% | +44.47 pp |
| Q3 2024 | 2024-09-30 | −12.12% | −39.69 pp |
| Q2 2024 | 2024-06-30 | −12.96% | +51.07 pp |
| Q1 2024 | 2024-03-31 | −33.41% | +44.40 pp |
| Q4 2023 | 2023-12-31 | −57.94% | +59.23 pp |
| Q3 2023 | 2023-09-30 | 27.57% | +171.41 pp |
| Q2 2023 | 2023-06-30 | −64.03% | +101.60 pp |
| Q1 2023 | 2023-03-31 | −77.81% | +64.12 pp |
| Q4 2022 | 2022-12-31 | −117.16% | +165.97 pp |
| Q3 2022 | 2022-09-30 | −143.84% | +68.39 pp |
| Q2 2022 | 2022-06-30 | −165.62% | +154.62 pp |
| Q1 2022 | 2022-03-31 | −141.93% | −152.91 pp |
| Q4 2021 | 2021-12-31 | −283.14% | +189.13 pp |
| Q3 2021 | 2021-09-30 | −212.22% | +254.65 pp |
| Q2 2021 | 2021-06-30 | −320.24% | +190.46 pp |
| Q1 2021 | 2021-03-31 | 10.98% | +709.67 pp |
| Q4 2020 | 2020-12-31 | −472.27% | +209.83 pp |
| Q3 2020 | 2020-09-30 | −466.87% | +146.12 pp |
| Q2 2020 | 2020-06-30 | −510.71% | −475.54 pp |
| Q1 2020 | 2020-03-31 | −698.70% | −483.31 pp |
| Q4 2019 | 2019-12-31 | −682.10% | −224.87 pp |
| Q3 2019 | 2019-09-30 | −612.99% | −347.26 pp |
| Q2 2019 | 2019-06-30 | −35.16% | +261.95 pp |
| Q1 2019 | 2019-03-31 | −215.38% | +106.01 pp |
| Q4 2018 | 2018-12-31 | −457.23% | +89.28 pp |
| Q3 2018 | 2018-09-30 | −265.73% | −319.04 pp |
| Q2 2018 | 2018-06-30 | −297.11% | — |
| Q1 2018 | 2018-03-31 | −321.40% | — |
| Q4 2017 | 2017-12-31 | −546.51% | — |
| Q3 2017 | 2017-09-30 | 53.31% | — |
| Q2 2016 | 2016-06-30 | −6,138.42% | −5729.65 pp |
| Q1 2016 | 2016-03-31 | −3,249.78% | −2509.24 pp |
| Q4 2015 | 2015-12-31 | −582.64% | — |
| Q3 2015 | 2015-09-30 | −1,014.42% | — |
| Q2 2015 | 2015-06-30 | −408.77% | — |
| Q1 2015 | 2015-03-31 | −740.54% | — |
BeOne Medicines net profit margin trends
Over the last five fiscal years, BeOne Medicines's net profit margin increased from −526.10% to 5.37%, a change of +531.47 percentage points. The latest reported quarter, Q2 2026, shows 13.90%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
